ArticleBMC biotechnology2025
Green synthesis of silver iodide nanoparticles from Kluyveromyces marxianus M59 beta-glucan: characterization and anticancer activity.
Article in BMC biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Biologically Mediated Nanoparticle Synthesis as a Potential Green Strategy: Principles, Methods, and Pharmaceutical Applications.Pharmaceutics · 2026Review
- Formation AgI and ZnINanomaterials (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Green synthesis of silver iodide nanoparticles (AgI-NPs) using carboxymethyl β-glucan from Kluyveromyces marxianus M59 was conducted to produce environmentally friendly and stable nanomaterials. The AgI-NPs had particle sizes ranging from 29 to 100 nm, exhibited a crystalline structure confirmed by X-ray diffraction, and and showed a characteristic absorption peak at 450 nm. Biological evaluations revealed low antibacterial activity against Listeria monocytogenes (maximum inhibition zone: 1.70 mm at 5 mg/mL), strong antibiofilm activity (66.9% reduction at 5 mg/mL), and significant antioxidant capacity, with the highest 2,2-diphenyl-1-picrylhydrazyl (DPPH) scavenging activity of 58.9% at 5 mg/mL. Cytotoxicity assays showed selective toxicity toward A549 lung cancer cells (IC50: 23.95 µg/mL at 24 h and 19.13 µg/mL at 48 h) compared to normal L929 fibroblasts (IC50: 130.37 µg/mL at 24 h and 73.69 µg/mL at 48 h). These findings highlight the multifunctional potential of AgI-NPs, emphasizing their antibiofilm, antioxidant, and anticancer activities, and provide a foundation for further investigations into their molecular mechanisms and sustainable applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.